A Safety Surveillance Study of Events of Special Interest Occurring in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Advanced Cell Technology (Primary)
- Indications Macular degeneration
- Focus Adverse reactions
- Sponsors Astellas Institute for Regenerative Medicine
- 18 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 08 Jun 2017 Planned End Date changed from 31 Dec 2029 to 1 Dec 2029.
- 08 Jun 2017 Planned primary completion date changed from 31 Dec 2029 to 1 Dec 2029.